Login to Your Account

Partner Merck Halts Enrollment

Vertex's Lead Aurora Kinase Inhibitor Hits Safety Snag

By Jennifer Boggs

Monday, November 26, 2007
Vertex Pharmaceuticals Inc.'s collaboration with Merck & Co. Inc. to develop Aurora kinase inhibitors in cancer encountered a bump in the road after preliminary safety data indicated a potential cardiovascular effect in one patient treated with lead candidate, MK-0457 (VX-680). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription